Antibiotic slashes exacerbation in neutrophilic COPD

Azithromycin significantly reduces the incidence of severe exacerbations of neutrophilic chronic obstructive pulmonary disease (COPD), but has little impact on other factors , according to a small Australian study.

The researchers randomised 30 patients to azithromycin 250mg daily or placebo for 12 weeks in addition to their standard respiratory medications.

The therapy resulted in a mean severe exacerbation rate of 0.33 per person per 26 weeks in the azithromycin group compared with 0.93 exacerbations per